Soluble IL-6R in Plasma Cell Dyscrasias

References

• Van De Poel H. W., Coebergh J. W. W., Hillen H. F. P. Malignant transformation of monoclonal garnopathy of undetermined significance among patients of a community hospital in South-eastern Netherlands. Br. J. Haem. 1995; 91: 121–125
   PubMed Web of Science ®Google Scholar
• Kyle R. A. Benign monoclonal gammopathy: after 20–35 years of follow up. Mayo. Clinic. Prvc. 1993; 68: 26–36
   PubMed Web of Science ®Google Scholar
• Kyle R. A. Why better prognostic factors for multiple myeloma are needed. Blood 1994; 83: 1713–1716
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1–10
   PubMed Web of Science ®Google Scholar
• Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243–1254
   PubMed Web of Science ®Google Scholar
• Hirano T., Yasukawa K., Hauda H., Taga T., Watanabe Y., Matsuda T., Kashiwanura S., Nakajima K., Koyama K., Iwamatsu A., Tsunasawa S., Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73–75
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X-G., Lu Z.-Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863–872
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Hshimoto T. Autocrine generation and requirement of BSF-21/IL-6 for multiple myelomas. Nature 1988; 332: 83–85
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.-G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by Interleukin-6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Anderson K. C., Jones R. M., Morimoto C., Leavitt P., Barut B. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73: 1915–1924
   PubMed Web of Science ®Google Scholar
• Nilsson K., Jernberg H., Petterson M. IL-6 as a growth factor for multiple myeloma cells- A short overview. Curr. Top. Micro. Imm. 1990; 166: 3–12
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.-G., Jourdan M., Portier M., Bataille R. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. Curr. Top. Micr. Imm. 1990; 166: 23–31
   PubMed Web of Science ®Google Scholar
• Gaillard J. P., Bataille R., Brailly H., Zuher C., Yasuka K., Attal M., Maruo N., Taga T., Kishimoto T., Klein B. Increased and stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gam-mopathy. Eur. J. Immunol. 1993; 23: 820–824
   PubMed Web of Science ®Google Scholar
• Uckun F. M. Regulation of human B-cell ontogeny. Blood 1990; 76: 1908–1923
   PubMed Web of Science ®Google Scholar
• Kincade P. W., Lee G., Pietrangeli C. E., Hayashi S.-I., Gimble I. M. Cells and molecules that regulate B lymphopoiesis in bone marrow. Ann. Rev. Immunol. 1989; 7: 111–143
   PubMed Web of Science ®Google Scholar
• Kincade P. W. Molecular interactions between stro-mal cells and B lymphocyte precursors. Semin. Immunol. 1991; 3: 379–390
   PubMedGoogle Scholar
• Berek C. The development of B cells and the B-cell repertoire in the microenvironment of the germinal centre. Immunol. Rev. 1992; 126: 519–524
   Web of Science ®Google Scholar
• Liu Y.-I., Johnson G. D., Gordon J., Maclennan I. C. M. Germinal centres in T-cell dependent antibody responses. Immunol. Today 1992; 13: 17–21
   PubMedGoogle Scholar
• Banchereau J., Rousset F. Human B lymphocytes: Phenotype, proliferation and differentiation. Adv. Immunol. 1992; 52: 125–261
   PubMed Web of Science ®Google Scholar
• Hilhert D. M., Cancro M. P., Scherle P. A., Nordan R. P., Van Snick J., Gerhard W., Rudikoff S. T cell derived IL-6 is differentially required for antigen-specific antibody secretion by primary and secondary B cells. J. Immunol. 1989; 143: 4019–4024
   PubMed Web of Science ®Google Scholar
• Raynal M. C., Liu Z. Y., Hirano T., Mayer L., Kishimoto T., Chenkiang S. Interleukin 6 induces secretion of IgGl by coordinated transcriptional activation and differential mRNA accumulation. Proc. Natl. Acad. Sc. U.S.A. 1989; 86: 8024–8028
   PubMed Web of Science ®Google Scholar
• Murakami M., Hibi M., Nakagawa N., Nakagawa T., Yasukawa K., Yamanishi K., Taga T., Kishimoto T. IL-6 induced homodimerisation of gp130 and associated activation of a tyrosine kinase. Science 1993; 260: 1808–1810
   PubMed Web of Science ®Google Scholar
• Macmillan R., Longmire R. L., Yelenosky R., Lang J. E., Heath V., Craddock C. G. Immunoglobulin synthesis by human lymphoid tissues: normal bone marrow as a major site of IgG production. J. Immunol. 1972; 109: 1386–94
   PubMed Web of Science ®Google Scholar
• Tew J. G., Dilosa R. M., Burton G. F., Kosco M. H., Kupp L. I., Masuda A., Szakal A. K. Germinal centres and antibody production in bone marrow. Immunol. Rev. 1992; 126: 99–112
   PubMed Web of Science ®Google Scholar
• Roldan E., Rodriguez C., Navas G., Parra C., Brieva J. A. Cytokine network regulating terminal maturation of human bone marrow B cells capable of spontaneous and high rate Ig secretion in vitro. J. Immunol. 1992; 149: 2367–2371
   PubMed Web of Science ®Google Scholar
• Muraguchi A., Hirano T., Tang B., Horii Y., Nakajima K., Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differential of B cells. J. Exp. Med. 1988; 167: 332–344
   PubMed Web of Science ®Google Scholar
• Roldan E., Garcia-Pardo A., Brieva J. A. VLA-4 fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate Ig secretion. J. Exp. Med. 1992; 175: 1739–1747
   PubMed Web of Science ®Google Scholar
• Asaoku H., Kawano M., Iwato K., Tanabe O., Tanaka H., Hirano T., Kishimoto T., Kuramoto A. Decrease in BSF-2/IL-6 in advanced cases of multiple myeloma. Blood 1988; 72: 429–432
   PubMed Web of Science ®Google Scholar
• Kawano M., Tanaka H., Ishikawa H., Nobuyoshi M., Iwato K., Asaoku H., Tanabe O., Kuramoto A. Interlekin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 1989; 73: 2145–2148
   PubMed Web of Science ®Google Scholar
• Zhang X. G., Klein B., Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11–13
   PubMed Web of Science ®Google Scholar
• Zhang X. G., Bataille R., Widjenes J., Klein B. Interleukin-6 dependence of advanced malignant plasma cell dyscrasis. Cancer 1992; 69: 1373–1376
   PubMed Web of Science ®Google Scholar
• Billadeau D., Ahmann G., Griepp P., Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant cell. J. Exp. Med. 1993; 178: 1023–1031
   PubMed Web of Science ®Google Scholar
• Bakkus M. H. C., Van Riet L., Van Camp B., Thielmans K. Evidence that the clonogenic cell in multiple myeloma originates from a preswitched but somatically mutated cell. Br. J. Haematol. 1994; 87: 68–74
   PubMed Web of Science ®Google Scholar
• Bakkus M. H. C., Van Riet L., De Greef C., Van Camp B., Thielmans K. The clonogenic precursor cell in multiple myeloma. Leukemia and Lymphoma 1995; 18: 221–229
   PubMed Web of Science ®Google Scholar
• Omede P., Boccarado M., Fusaro A., Gallone G., Pileri A. Multiple myeloma: ‘early’ plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. Br. J. Haematol. 1993; 85: 504–513
   PubMed Web of Science ®Google Scholar
• Joshua D., Petersen A., Brown R., Pope B., Snowdon L., Gibson J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelo-matosis. Br. J. Haematol. 1996; 94: 76–81
   PubMed Web of Science ®Google Scholar
• Tanabe O., Kawano M., Tanaka H., Iwato K., Asaoku H., Ishikawa H., Nobuyoshi M., Hirano T;, Kishimoto T., Kuramoto A. BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am. J. Hematol. 1989; 31: 258–262
   PubMed Web of Science ®Google Scholar
• Pelhiemi T.-T., Irjala K., Mattila K., Pulkki K., Rajamaki A., Tienhara A., Laakso M., Lahtiten R. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995; 85: 765–771
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X.-G., Klein B. Serum levels of interleukin-6, a potent myeloma growth factor as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest. 1989; 84: 2008–2001
   PubMed Web of Science ®Google Scholar
• Reibnegger G., Krainer M., Herold M., Ludwig H., Wachter H., Huber H. Predictive value of interleukin-6 and neoptrin in patients with multiple myeloma. Cancer Res. 1991; 51: 6250–6253
   PubMed Web of Science ®Google Scholar
• Tienhaara A., Pulkki K., Mattila K., Irjala K., Pelliniemie T.-T. Serum immunoreactive interleukin-6 and C-reactive protein in patients with multiple myeloma at diagnosis. Br. J. Haem. 1994; 86: 391–393
   PubMed Web of Science ®Google Scholar
• Smith S., Morgan L. Immunoreactive Interleukin-6 and C-reactive protein in plasma cell disorders. Br. J. Haem. 1994; 87: 883–884
   PubMed Web of Science ®Google Scholar
• Boccadoro M., Gallone G., Frieri R., Pileri A., Bataille R., Klein B. Plasma cell labelling index, β2 microglobulin, and C-reactive protein: What is the best combination for prognosis?. Blood 1993; 82: 3507–3508
   PubMed Web of Science ®Google Scholar
• Bataille R., Barlogie B., Lu Z. Y., Rossi J. F., Lavabre-Bertrand T., Beck T., Wijdenes J., Brochier J., Klein B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685–91
   PubMed Web of Science ®Google Scholar
• Heinrich P. C., Castell J. W., Andus T. Interleukin-6 and the acute phase response. Biochem. J. 1990; 265: 621–636
   PubMed Web of Science ®Google Scholar
• Baumann H., Gauldie J. The acute phase response. Immunol. Today 1994; 15: 74–80
   PubMedGoogle Scholar
• Yamasaki K., Taga T., Hirata H., Yawata Y., Kawanishi Y., Seed B., Taniguchi T., Hirano T., Kishimoto T. Cloning and expression of the human interleukin 6 (BSF-2/IFNb2) receptor. Science 1988; 241: 825–828
   PubMed Web of Science ®Google Scholar
• Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer. gp130. Cell 1990; 63: 1149–1157
   PubMed Web of Science ®Google Scholar
• Nakajima K., Matsuda T., Fujitani Y., Hirotada K., Yamanaka Y., Nakae K., Takeda T., Hirano T. Signal transduction through IL-6 receptor: Involvement of multiple protein kinases, stat factors, and a novel H7-sensitive pathway. Ann. N. Y. Acad. Sci. 1995; 762: 55–70
   PubMed Web of Science ®Google Scholar
• Heaney M. L., Golde D. W. Soluble cytokine receptors. Blood 1996; 87: 845–857
   Google Scholar
• Taga T., Narazaki M., Yasukawa K., Saito T., Miki D., Hamaguchi M., Davis S., Shoyab M., Yancoupoulos G. D., Kishimoto T. Functional inhibition of hematopoi-etic-and neurotropic-cytokines (LIF, OM and CNTF) by blocking IL-6 signal transducer, gp130. Proc. Natl. Acud. Sci. U.S.A 1992; 89: 10998–11001
   PubMed Web of Science ®Google Scholar
• Rose-John S., Ehlers M., Grotzinger J., Mullberg J. The soluble interleukin-6 receptor. Ann. N. Y. Acad. Sci. 1995; 762: 207–220
   PubMed Web of Science ®Google Scholar
• Honda M., Yamamoto S., Cheng M., Yasukawa Ki, Suzuki H., Saito T., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J. Immunol. 1992; 148: 2175–2180
   PubMed Web of Science ®Google Scholar
• Rose-John S., Heinrich P. C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 1994; 300: 281–290
   PubMed Web of Science ®Google Scholar
• Narazaki M., Yasukawa T., Saito T., Ohsugi Y., Fukui H., Koishihara Y., Yancopoulos G. D., Taga T., Kishimoto T. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82: 1–7
   PubMedGoogle Scholar
• Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv. Immunol. 1993; 54: 1–78
   PubMed Web of Science ®Google Scholar
• Mullberg J., Scooltink H., Stoyan T., Gunther M., Graeve L., Buse G., Mackiewicz A., Heinrich P. C., Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 1993; 23: 473–480
   PubMed Web of Science ®Google Scholar
• Mullberg J., Dittrich E., Graeve L., Gerhart C., Yasukawa K., Taga T., Kishimoto T., Heinrich P. C., Rose-John S. Differential shedding of the two subunits of the interleukin-6 receptor. FEBS LETTERS 1993; 332: 174–178
   PubMed Web of Science ®Google Scholar
• Lust J. A., Donovan K. A., Kline M. P., Greipp P. R., Kyle R. A., Maihle N. J. Isolation of a mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 7992; 4: 96–100
   Google Scholar
• May L. T., Nduhuisi M. I., Patel K., Garcia D. Interleukin-6 chaperones in blood. Ann. N. Y. Acad. Sci. 1995; 621: 20–128
   Google Scholar
• Ohtani K., Ninomiya H., Hasegawa Y., Kobayashi T., Kojima H., Nagasawa T., Abe T. Clinical significance of elevated soluble interluekin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Br. J. Haem. 1996; 91: 116–120
   Web of Science ®Google Scholar
• Smith S. R., Morgan L. Clinical significance of elevated soluble interleukin 6 receptor levels in patients with plasma cell disorders. Br. J. Haem. 1996; 92: 766–767
   Google Scholar
• Pulkki K., Pelliniemi T.-T., Rajamaki A., Tienhaara A., Laakso M., Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br. J. Haem. 1996; 92: 370–374
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Gaillard J. P., Kalish L. A., Oken M. M., Miller A. M., Kyle R. A., Klein B. Independent prognostic value for serum soluble interleukin-6 receptor (sIL-6R) in Eastern Cooperative Oncology Group (ECOG) myeloma trial E9487. Proc. Am. Soc. Clin. Oncol. 1993; 12: 404
   Google Scholar
• Joshua D. E., Brown R. D., Gibson J. Prognostic factors in myeloma: What they tell us about the pathophysiol-ogy of the disease. Leukaemia and Lymphoma 1994; 15: 375–381
   PubMed Web of Science ®Google Scholar
• Smith S. R., Auerbach B., Morgan L. Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders. Br. J. Haem. 1996; 92: 67–70
   PubMed Web of Science ®Google Scholar
• Ong F., Kaiser U., Seelen P. J., Hermans J., Wijermans P. W., De Kieviet W., Jacques G., Luin-Nelemans J. C. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinaemias due to other causes. Blood 1996; 87: 712–716
   PubMed Web of Science ®Google Scholar
• Griepp P. R., Lust J. A., O'Fallon W. M., Katzmann J. A., Witzig T. E., Kyle R. A. Plasma cell labelling index and β2--microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387
   PubMed Web of Science ®Google Scholar
• Bataille R., Boccadoro M., Klein B., Dune B., Pileri A. C-reactive protein and β2--microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–737
   PubMed Web of Science ®Google Scholar